Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with ...

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, ...

Phase 2b SunRISe-1 data showed TAR-200 monotherapy achieved an 82.4% complete response rate in BCG-unresponsive, high-risk ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

The key takeaways are that prostate cancer misinformation is widespread across online platforms and spans many different ...

Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy that is being studied for the treatment of bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC) that is ...

Data from the phase 3 BOND-003 trial (NCT04452591), presented at the 2025 American Urological Association Annual Meeting, demonstrated that intravesical cretostimogene grenadenorepvec (CG0070) is a ...

An expert discusses how the diagnosis and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) require careful recognition of characteristic dermatologic and hematologic features, with ...

Levee Medical has begun its pivotal ARID II trial, studying the Voro Scaffold for improved continence after prostatectomy.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Jethro C.C. Kwong, a urology resident from the University of Toronto, discusses a novel artificial intelligence (AI)-based ...